Serum osteopontin concentration is decreased by exercise-induced fat loss but is not correlated with body fat percentage in obese humans

You,Jeong  Soon; Ji,Hye-In; Chang,Kyung  Ja; Yoo,Myung  Chul; Yang,Hyung-In; Jeong,In-Kyung; Kim,Kyoung  Soo

doi:10.3892/mmr.2013.1522

Serum osteopontin concentration is decreased by exercise-induced fat loss but is not correlated with body fat percentage in obese humans

Authors:
- Jeong Soon You
- Hye-In Ji
- Kyung Ja Chang
- Myung Chul Yoo
- Hyung-In Yang
- In-Kyung Jeong
- Kyoung Soo Kim
View Affiliations

Affiliations: Department of Food and Nutrition, Inha University, Nam-gu, Incheon 402-751, Republic of Korea, East-West Bone and Joint Disease Research Institute, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Gangdong-gu, Seoul 134-727, Republic of Korea, Department of Endocrinology, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Gangdong-gu, Seoul 134-727, Republic of Korea
Published online on: June 13, 2013 https://doi.org/10.3892/mmr.2013.1522
Pages: 579-584

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To evaluate the extent to which fat mass contributes to serum osteopontin (OPN) concentration, we investigated whether serum OPN levels are decreased by exercise-induced fat mass loss and whether they are associated with body fat percentage in obese humans. Twenty‑three female college students were recruited to participate in an 8‑week body weight control program. Body composition [body weight, soft lean mass, body fat mass, body fat percentage, waist-hip ratio and body mass index (BMI)] were assessed prior to and following the program. Serum lipid profiles and serum adiponectin, leptin and osteopontin levels were measured from serum collected prior to and following the program. To understand the effect of fat mass loss on the serum levels of adipokine, which is mainly produced in adipose tissue, the leptin and adiponectin levels were also measured prior to and following the program. Serum leptin levels (mean ± standard error of the mean) decreased significantly following the program (from 9.82±0.98 to 7.23±0.67 ng/ml) and were closely correlated with body fat percentage. In addition, serum adiponectin levels were negatively correlated with body fat percentage, while serum adiponectin levels were not significantly altered. By contrast, serum OPN levels decreased significantly following the program (from 16.03±2.34 to 10.65±1.22 ng/ml). However, serum OPN levels were not correlated with body fat percentage, suggesting that serum OPN levels are controlled by several other factors in humans. In conclusion, a high expression of OPN in adipose tissues may not be correlated with serum OPN levels in obese humans. Thus, tissues or physiological factors other than fat mass may have a greater contribution to the serum OPN levels.

View Figures

View References

1	Harford KA, Reynolds CM, McGillicuddy FC and Roche HM: Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc. 70:408–417. 2011. View Article : Google Scholar : PubMed/NCBI
2	Morimoto J, Kon S, Matsui Y and Uede T: Osteopontin; as a target molecule for the treatment of inflammatory diseases. Curr Drug Targets. 11:494–505. 2010. View Article : Google Scholar : PubMed/NCBI
3	Nomiyama T, Perez-Tilve D, Ogawa D, et al: Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 117:2877–2888. 2007. View Article : Google Scholar : PubMed/NCBI
4	Kiefer FW, Zeyda M, Todoric J, et al: Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology. 149:1350–1357. 2008. View Article : Google Scholar
5	Gómez-Ambrosi J, Catalán V, Ramírez B, et al: Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab. 92:3719–3727. 2007.PubMed/NCBI
6	Xu G, Sun W, He D, et al: Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol. 32:410–416. 2005.PubMed/NCBI
7	Braitch M and Constantinescu CS: The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Inflamm Allergy Drug Targets. 9:249–256. 2010. View Article : Google Scholar : PubMed/NCBI
8	Frenzel DF and Weiss JM: Osteopontin and allergic disease: pathophysiology and implications for diagnostics and therapy. Expert Rev Clin Immunol. 7:93–109. 2011. View Article : Google Scholar : PubMed/NCBI
9	Waller AH, Sanchez-Ross M, Kaluski E and Klapholz M: Osteopontin in cardiovascular disease: a potential therapeutic target. Cardiol Rev. 18:125–131. 2010. View Article : Google Scholar : PubMed/NCBI
10	Naldini A, Leali D, Pucci A, et al: Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol. 177:4267–4270. 2006. View Article : Google Scholar : PubMed/NCBI
11	Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16:79–87. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kiefer FW, Neschen S, Pfau B, et al: Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia. 54:2132–2142. 2011. View Article : Google Scholar : PubMed/NCBI
13	Zeyda M, Gollinger K, Todoric J, et al: Osteopontin is an activator of human adipose tissue macrophages and directly affects adipocyte function. Endocrinology. 152:2219–2227. 2011. View Article : Google Scholar : PubMed/NCBI
14	Komorowski J, Jankiewicz-Wika J, Kolomecki K, et al: Systemic blood osteopontin, endostatin, and E-selectin concentrations after vertical banding surgery in severely obese adults. Cytokine. 55:56–61. 2011. View Article : Google Scholar
15	Schaller G, Aso Y, Schernthaner GH, et al: Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance. Obes Surg. 19:351–356. 2009. View Article : Google Scholar : PubMed/NCBI
16	Shevde LA, Das S, Clark DW and Samant RS: Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 10:71–81. 2010. View Article : Google Scholar : PubMed/NCBI
17	Giachelli CM and Steitz S: Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 19:615–622. 2000. View Article : Google Scholar : PubMed/NCBI
18	Reinholt FP, Hultenby K, Oldberg A and Heinegård D: Osteopontin - a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA. 87:4473–4475. 1990. View Article : Google Scholar : PubMed/NCBI
19	Friedewald WT, Levy RI and Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:499–502. 1972.PubMed/NCBI
20	Sowers MR and Karvonen-Gutierrez CA: The evolving role of obesity in knee osteoarthritis. Curr Opin Rheumatol. 22:533–537. 2011. View Article : Google Scholar : PubMed/NCBI
21	Shehzad A, Ha T, Subhan F and Lee YS: New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur J Nutr. 50:151–161. 2011. View Article : Google Scholar : PubMed/NCBI
22	Trayhurn P and Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 92:347–355. 2004. View Article : Google Scholar : PubMed/NCBI
23	Wärnberg J, Cunningham K, Romeo J and Marcos A: Physical activity, exercise and low-grade systemic inflammation. Proc Nutr Soc. 69:400–406. 2010.PubMed/NCBI
24	Gleeson M, Bishop NC, Stensel DJ, et al: The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 11:607–615. 2011. View Article : Google Scholar : PubMed/NCBI
25	Klempel MC and Varady KA: Reliability of leptin, but not adiponectin, as a biomarker for diet-induced weight loss in humans. Nutr Rev. 69:145–154. 2011. View Article : Google Scholar : PubMed/NCBI
26	Frühbeck G, Gómez-Ambrosi J, Muruzábal FJ and Burrell MA: The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab. 280:E827–E847. 2001.PubMed/NCBI
27	Arita Y, Kihara S, Ouchi N, et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity 1999. Biochem Biophys Res Commun. 31:560–564. 2012.PubMed/NCBI
28	Shehzad A, Iqbal W, Shehzad O and Lee YS: Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens). 11:8–20. 2012.PubMed/NCBI
29	Guerre-Millo M: Adiponectin: an update. Diabetes Metab. 34:12–18. 2008. View Article : Google Scholar
30	Riedl M, Vila G, Maier C, et al: Plasma osteopontin increases after bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. J Clin Endocrinol Metab. 93:2307–2312. 2008. View Article : Google Scholar : PubMed/NCBI
31	Humphries B, Fenning A, Dugan E, et al: Whole-body vibration effects on bone mineral density in women with or without resistance training. Aviat Space Environ Med. 80:1025–1031. 2009. View Article : Google Scholar : PubMed/NCBI
32	Smith EL and Gilligan C: Physical activity effects on bone metabolism. Calcif Tissue Int. 49(Suppl): S50–S54. 1991. View Article : Google Scholar
33	Reis CE, Bressan J and Alfenas RC: Effect of the diet components on adiponectin levels. Nutr Hosp. 25:881–888. 2010.PubMed/NCBI
34	Tamura A, Shingai M, Aso N, et al: Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. Circ J. 67:742–744. 2003. View Article : Google Scholar : PubMed/NCBI
35	Oh KW, Lee WY, Rhee EJ, et al: The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf). 63:131–138. 2005. View Article : Google Scholar : PubMed/NCBI
36	Villareal DT, Fontana L, Weiss EP, et al: Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch Intern Med. 166:2502–2510. 2006. View Article : Google Scholar : PubMed/NCBI